As a basis of 4D Cellome, innovative technology that enables comprehensive and quantitative acquisition and analysis of spatiotemporal information in single cell should be developed. Such ...

4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150. The company will only have to conduct a ...